{"id":63700,"date":"2026-10-21T08:11:47","date_gmt":"2026-10-21T08:11:47","guid":{"rendered":"https:\/\/ibima.eu\/?page_id=63700"},"modified":"2026-10-21T08:17:13","modified_gmt":"2026-10-21T08:17:13","slug":"nanodiagncd-2027","status":"publish","type":"page","link":"https:\/\/ibima.eu\/en\/nanodiagncd-2027\/","title":{"rendered":"NanoDiagNCD 2027"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbsection\u00bb _builder_version=\u00bb4.25.1&#8243; custom_padding=\u00bb||0px|||\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_5,3_5,1_5&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb21px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/10\/ERA4Health-logo-1.png\u00bb title_text=\u00bbERA4Health logo\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb54%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb26px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb alt=\u00bbERA4Health logo\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb59px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbNanoDiagNCD 2027 \u2013 Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3&#8243; title_line_height=\u00bb1.3em\u00bb module_alignment=\u00bbcenter\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb1px|-78px|||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p style=\"text-align: justify;\">La Asociaci\u00f3n Europea ERA4Health ha preanunciado la convocatoria <strong>NanoDiagNCD 2027 \u2013 Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases<\/strong>, destinada a financiar proyectos de investigaci\u00f3n traslacional que desarrollen y\/o validen herramientas diagn\u00f3sticas y teran\u00f3sticas basadas en nanotecnolog\u00edas para mejorar la detecci\u00f3n y el manejo cl\u00ednico de las enfermedades no transmisibles.<\/p>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbObjetivos de la convocatoria\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\u00bbrow\u00bb _builder_version=\u00bb4.25.1&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb77.1%\u00bb custom_margin=\u00bb|-259px|-31px|161px||\u00bb custom_padding=\u00bb|0px|0px|9px||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.16&#8243; custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb11px|-78px|||false|false\u00bb custom_padding=\u00bb||0px|||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p style=\"text-align: justify;\">El objetivo de NanoDiagNCD 2027 es apoyar proyectos de investigaci\u00f3n traslacional que utilicen nanotecnolog\u00edas, solas o combinadas con tecnolog\u00edas facilitadoras clave (<em>Key Enabling Technologies<\/em>), para desarrollar y validar herramientas diagn\u00f3sticas y teran\u00f3sticas innovadoras.<\/p>\n<p style=\"text-align: justify;\">Las propuestas deber\u00e1n basarse en evidencia cient\u00edfica s\u00f3lida y contribuir a optimizar el continuo asistencial, incluyendo:<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul style=\"text-align: justify;\">\n<li>La prevenci\u00f3n y la detecci\u00f3n temprana de enfermedades no transmisibles.<\/li>\n<li>La monitorizaci\u00f3n de la enfermedad.<\/li>\n<li>La orientaci\u00f3n y selecci\u00f3n del tratamiento.<\/li>\n<li>La evaluaci\u00f3n de efectos adversos y del balance beneficio-riesgo.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb4px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbLas propuestas deber\u00e1n\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb43px\u00bb custom_margin=\u00bb-12px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb11px||||false|false\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"text-align: justify;\">Definir y validar valores de referencia del rendimiento de las nuevas herramientas frente a los enfoques diagn\u00f3sticos existentes.<\/li>\n<li style=\"text-align: justify;\">Demostrar un valor a\u00f1adido en aspectos como sensibilidad, especificidad, accesibilidad, asequibilidad, comodidad para el paciente, invasividad y\/o seguridad.<\/li>\n<li style=\"text-align: justify;\">Considerar desde cualquier fase del proyecto los requisitos para su traslaci\u00f3n y adopci\u00f3n cl\u00ednica, incluyendo escalabilidad, fabricabilidad, estandarizaci\u00f3n, coste-efectividad, preparaci\u00f3n regulatoria, interoperabilidad e integraci\u00f3n en los sistemas sanitarios.<\/li>\n<li style=\"text-align: justify;\">En el caso de las herramientas teran\u00f3sticas, aplicar el principio de \u00abdiagn\u00f3stico primero\u00bb, de forma que el diagn\u00f3stico permita seleccionar la terapia.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb min_height=\u00bb158.9px\u00bb custom_margin=\u00bb9px|auto||159px|false|false\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbOut of scope\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb21px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||-28px|||\u00bb custom_padding=\u00bb|||11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"text-align: justify;\">No sit\u00faen la nanotecnolog\u00eda como elemento central del proyecto.<\/li>\n<li style=\"text-align: justify;\">Se centren en el descubrimiento de nuevos biomarcadores (Se permitir\u00eda el desarrollo de herrramientas basdas en biomarcadores conocidos, como la mejora de pruebas existentes, la integraci\u00f3n de varios biomarcadores en una misma plataforma o la optimizaci\u00f3n de su uso para nuevas aplicaciones).<\/li>\n<li style=\"text-align: justify;\">Aborden enfermedades infecciosas. Se permiten estudios sobre enfermedades cr\u00f3nicas derivadas de infecciones pasadas.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-23px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbCondiciones generales\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb49px||||false|false\u00bb custom_padding=\u00bb7px|||||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb custom_padding__hover=\u00bb21px|||||\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Las propuestas deber\u00e1n contar con un m\u00ednimo de tres socios de tres pa\u00edses diferentes elegibles para financiaci\u00f3n.<\/li>\n<li style=\"text-align: justify;\">Pa\u00edses participantes: B\u00e9lgica, Egipto, Francia<em>, Grecia<\/em>, Hungr\u00eda, Israel, Italia , Letonia, Lituania, Noruega, Pa\u00edses Bajos, Polonia, Portugal, Ruman\u00eda, Eslovaquia, Espa\u00f1a, Taiw\u00e1n y Turqu\u00eda.<\/li>\n<li style=\"text-align: justify;\">Se requiere un enfoque interdisciplinar y transdisciplinar, as\u00ed como la participaci\u00f3n de m\u00faltiples partes interesadas.<\/li>\n<li style=\"text-align: justify;\">Los proyectos deber\u00e1n incluir un <em>Impact Plan<\/em> que describa c\u00f3mo contribuir\u00e1n a la transformaci\u00f3n de los sistemas alimentarios y explicar su complementariedad con proyectos financiados previamente.<\/li>\n<li style=\"text-align: justify;\">\n<p data-start=\"1418\" data-end=\"1521\" style=\"text-align: justify;\">IBIMA pordr\u00e1 participar a trav\u00e9s de la Consejer\u00eda de Presidencia, Sanidad y Emergencias o del Intituto de Salud Carlos III.\u00a0<\/p>\n<\/li>\n<li style=\"text-align: justify;\">Es una convocatoria dos fases.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb min_height=\u00bb268px\u00bb custom_margin=\u00bb-14px|auto||159px|false|false\u00bb custom_padding=\u00bb0px||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbfechas clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong>17 de noviembre<\/strong>: Publicaci\u00f3n oficial de la convocatoria.\u00a0<\/li>\n<li><strong>19 de noviembre<\/strong>: Infoday<\/li>\n<li><strong>19 de enero<\/strong>: Deadline 1\u00aa Fase<\/li>\n<li><strong style=\"font-size: 14px;\">9 de Junio<\/strong><span style=\"font-size: 14px;\">: Deadline Full Stage<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-80px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbDocumentaci\u00f3n y enlaces clave\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb hover_enabled=\u00bb0&#8243; sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|||11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><a href=\"https:\/\/era4health.eu\/calls\/pre_NanoDiagNCD2027.php\"><strong>P\u00e1gina web y preanuncio<\/strong><\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Asociaci\u00f3n Europea ERA4Health ha preanunciado la convocatoria NanoDiagNCD 2027 \u2013 Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases, destinada a financiar proyectos de investigaci\u00f3n traslacional que desarrollen y\/o validen herramientas diagn\u00f3sticas y teran\u00f3sticas basadas en nanotecnolog\u00edas para mejorar la detecci\u00f3n y el manejo [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-63700","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NanoDiagNCD 2027 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/nanodiagncd-2027\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NanoDiagNCD 2027 - Ibima\" \/>\n<meta property=\"og:description\" content=\"La Asociaci\u00f3n Europea ERA4Health ha preanunciado la convocatoria NanoDiagNCD 2027 \u2013 Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases, destinada a financiar proyectos de investigaci\u00f3n traslacional que desarrollen y\/o validen herramientas diagn\u00f3sticas y teran\u00f3sticas basadas en nanotecnolog\u00edas para mejorar la detecci\u00f3n y el manejo [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/nanodiagncd-2027\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-21T08:17:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/nanodiagncd-2027\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/nanodiagncd-2027\\\/\",\"name\":\"NanoDiagNCD 2027 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2026-10-21T08:11:47+00:00\",\"dateModified\":\"2026-10-21T08:17:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/nanodiagncd-2027\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/nanodiagncd-2027\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/nanodiagncd-2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NanoDiagNCD 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NanoDiagNCD 2027 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/nanodiagncd-2027\/","og_locale":"en_GB","og_type":"article","og_title":"NanoDiagNCD 2027 - Ibima","og_description":"La Asociaci\u00f3n Europea ERA4Health ha preanunciado la convocatoria NanoDiagNCD 2027 \u2013 Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases, destinada a financiar proyectos de investigaci\u00f3n traslacional que desarrollen y\/o validen herramientas diagn\u00f3sticas y teran\u00f3sticas basadas en nanotecnolog\u00edas para mejorar la detecci\u00f3n y el manejo [&hellip;]","og_url":"https:\/\/ibima.eu\/en\/nanodiagncd-2027\/","og_site_name":"Ibima","article_modified_time":"2026-10-21T08:17:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/nanodiagncd-2027\/","url":"https:\/\/ibima.eu\/es\/nanodiagncd-2027\/","name":"NanoDiagNCD 2027 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2026-10-21T08:11:47+00:00","dateModified":"2026-10-21T08:17:13+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/nanodiagncd-2027\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/nanodiagncd-2027\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/nanodiagncd-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"NanoDiagNCD 2027"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/63700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=63700"}],"version-history":[{"count":4,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/63700\/revisions"}],"predecessor-version":[{"id":63707,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/63700\/revisions\/63707"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=63700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}